Thumbay Lab for AI in Healthcare opens at Gulf Medical University

IMT News Desk
IMT News Desk
· 2 min read

The Thumbay College of Management and AI in Healthcare is collaborating with over 15 leading industry partners

The Thumbay College of Management and AI in Healthcare at Gulf Medical University (GMU) inaugurated the state-of-the-art Thumbay Lab for AI in Healthcare. The event took place at the University’s Library Main Foyer and was attended by dignitaries, faculty members, industry partners, and students.

The ceremony was graced by Sunjay Sudhir, Ambassador of India to the UAE, as the Chief Guest, and presided over by Dr Thumbay Moideen, Founder President, Thumbay Group.

The lab is a key infrastructure addition under the Thumbay College of Management and AI in Healthcare and complements a suite of academic programs, including:

· Master in Artificial Intelligence and Health Informatics (MAIHI)

· Certificate Course in Artificial Intelligence in Healthcare

· Certificate Course in Generative AI (GenAI) in Healthcare

These programmes are already open for admission and are designed to equip professionals and technologists with the skills to lead in AI-integrated healthcare environments.

Dr Thumbay Moideen stated, “This lab reflects our commitment to integrating artificial intelligence into every aspect of medical education and healthcare delivery. It will catalyse innovation, supporting students and researchers as they develop solutions that shape the future of healthcare.”

Prof Manda Venkatramana, Acting Chancellor of Gulf Medical University and Vice Chancellor – Academics, added, “This lab will significantly enrich the academic experience of our students by giving them hands-on exposure to emerging technologies. It also opens new avenues for collaborative research, innovation, and real-world problem-solving in healthcare.”

As part of its strategic ecosystem, the Thumbay College of Management and AI in Healthcare is proud to be collaborating with over 15 leading industry partners, including health-tech innovators, AI solution providers, and academic collaborators who contribute to real-time learning and industry-relevant project development.

Read Next

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences
Global News
January 20, 2026

Agenus announces closing of $141 M strategic collaboration with Zydus Lifesciences

To advance BOT+BAL and strengthen US manufacturing readiness Agenus, a leader in immuno-oncology innovation, announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialisation of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination programme. The collaboration provides Agenus with strategic capital and […]
Article by: IMT News Desk
Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia
Global News
January 16, 2026

Venus Remedies secures marketing authorisation for Ceftazidime + Avibactam in Indonesia

Approval marks Venus Remedies’ first anti-infective marketing authorisation in Indonesia and enables the country’s first generic entry for this critical antibiotic combination Venus Remedies has secured the marketing authorisation from the Indonesian regulatory authority for its combination antibiotic, Ceftazidime + Avibactam. This approval represents Venus Remedies’ first marketing authorization in the anti-infective segment in Indonesia […]
Article by: IMT News Desk
Wegovy pill approved in the US for weight management
Global News
December 26, 2025

Wegovy pill approved in the US for weight management

Novo Nordisk expects to launch the Wegovy pill in the US in early January 2026 Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse […]
Article by: IMT News Desk
Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK
Global News
December 24, 2025

Samsung Biologics America in agreement to acquire 100 per cent of Human Genome Sciences from GSK

Under the terms of the agreement, with closing anticipated toward the end of Q1 of 2026, Samsung Biologics will acquire the Rockville assets for $280 million Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced that its wholly owned US subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100 […]
Article by: IMT News Desk